“Science-backed.” “Clinically proven.” “Clinically studied.”
I see phrases like these constantly in advertising for supplements and other consumer health products. They are meant to sound reassuring because they seem to answer an important question before we even ask it: Does this product actually work?
In Canada, companies cannot simply say whatever they want. Health Canada’s current advertising-policy page points advertisers to the Guidelines for Consumer Advertising of Health Products. Those guidelines say therapeutic claims must stay within a product’s authorized Terms of Market Authorization, and that statistics, journal articles and study results must be consistent with – and not expand – the product’s Terms of Market Authorization.
The Competition Bureau’s current guidance on performance claims adds another layer. Claims about a product’s performance or effectiveness must be based on an “adequate and proper” test conducted before the claim is made, and the testing must support the general impression created by the marketing.
So, there are rules. Yet there can still be a gap between a claim being supportable and a consumer understanding what evidence supports it.
Consider Elevate, a natural health product sold in Canada by Blue Star Nutraceuticals. On the company’s Canadian product page, Blue Star says the product’s key ingredients have been “scientifically shown” to support several outcomes, including a 25 per cent increase in memory quotient, 54 per cent preservation of reaction time and 41 per cent reduction in memory errors. Elsewhere on the page, it says every ingredient is “backed by science;” describes Elevate’s ingredients as “backed by clinical studies;” and labels them “Science Backed Ingredients.” The studies cited for the three numerical claims concern Huperzine A or Ginkgo biloba rather than the finished Elevate formulation.
The company’s own technical white paper, linked directly from its product page, makes that distinction explicit. It says the document summarizes “ingredient-specific evidence” supporting the product’s licensed uses and that the mechanisms described “do not imply clinical outcomes for the finished product.”
Elevate is also an authorized natural health product. Health Canada’s Licensed Natural Health Products Database lists Natural Product Number (NPN) 80109809 as active and marketed, with authorized uses including helping to enhance cognitive function in adults, helping to enhance memory in adults and helping to support peripheral circulation.
None of this establishes that Elevate’s advertising is non-compliant, and I am not suggesting that it is. The example illustrates a different problem: “science-backed” can sit on top of several very different kinds of evidence.
A plausible mechanism can help explain how something might work. But an Agency for Healthcare Research and Quality framework on mechanistic evidence separates mechanistic knowledge from direct evidence linking an intervention to a clinical outcome. Animal evidence can take us another step, but it still has important limitations. A systematic scoping review of animal-to-human translation found wide variation in how well animal findings translated to humans. In practical terms, a result in animals does not by itself tell us whether the same benefit will occur in people.
Even human studies do not all answer the same question. A BMJ meta-epidemiological study found that randomized trials using surrogate primary outcomes reported larger treatment effects, on average, than trials using final patient-relevant outcomes. And a meta-epidemiological study of how evidence changes after first trials found that results often changed as more evidence accumulated; large initial effects were especially likely to diminish.
Who funded the research matters, too. A Cochrane systematic review of industry sponsorship covering drug and medical-device research found that industry-sponsored studies were more likely to report favourable efficacy results and favourable conclusions. That review was not about wellness products specifically, so it cannot tell us whether the same association applies in this market, or how large it might be. But it does show why funding source is relevant when deciding how much confidence to place in evidence used to market a product.
Canada’s natural health product system itself recognizes that evidence is not one-size-fits-all. Health Canada’s guidance for natural health products making modern health claims says evidence requirements vary with the proposed claim and the product’s risk profile: higher-risk, higher-level claims require stronger and more certain evidence, while lower-risk claims can be supported by lower-level or less certain efficacy evidence when there is high certainty about safety.
Obtaining an NPN is meaningful. Health Canada says a natural health product must be safe, effective and of high quality to be licensed, and that an NPN means the product has been authorized for sale and is safe and effective when used according to the instructions on its label. But an NPN beside “science-backed” advertising still does not tell a consumer whether the evidence being highlighted came from the finished product, an ingredient, one study or a larger body of research – or who funded it.
That transparency question especially matters online. Health Canada’s current preclearance page says independent preclearance of health-product advertising remains voluntary for industry, although Health Canada strongly recommends it. Industry remains responsible for meeting federal advertising requirements.
The Canadian Public Health Association’s October 2026 position statement on digital platforms and online harm adds a broader public-health perspective. It says misleading marketing content can promote ineffective or harmful products, with potential consequences including financial loss, delayed or unsafe treatment and increased health-system costs. CPHA also calls for “defined standards for advertising on online platforms.”
CPHA describes digital literacy as essential but cautions that foregrounding it as a policy solution can deflect public attention and platform accountability. That principle is relevant here. Canadians can ask whether the finished product was studied, whether the outcome mattered, who funded the research and whether the finding has been independently replicated. But expecting every consumer to reconstruct an evidence hierarchy while scrolling through an advertisement is asking a lot.
A useful next step is greater transparency. When health-product advertising prominently invokes science, it should make clearer what kind of evidence is being invoked. If the supporting studies concern individual ingredients rather than the finished product, that distinction should be prominent. Digital promotion of licensed natural health products could make the NPN and authorized Health Canada claims easy to access where the marketing claim appears.
Those are policy options, not an argument that every wellness product should be regulated like a prescription medicine.
The underlying principle is simpler: scientific language should not carry more certainty than the evidence itself.
If a company wants to borrow the authority of science to sell a health product, consumers should be able to see what kind of science they are being asked to trust.
